⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386935 | 1.00 | — | — | |
| SCHEMBL1427764 | 0.79 | — | — | |
| SCHEMBL31514804 | 0.79 | — | — | |
| SCHEMBL232179 | 0.79 | — | — | |
| SCHEMBL29987283 | 0.79 | — | — | |
| SCHEMBL10153693 | 0.75 | — | — | |
| SCHEMBL21564632 | 0.75 | — | — | |
| SCHEMBL20969344 | 0.75 | — | — | |
| SCHEMBL364483 | 0.75 | — | — | |
| SCHEMBL16083962 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014801-B | Green production process of 2, 3-difluoro-5-chloropyridine with low single impurity content | 江苏丰山生化科技有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-114014801-A | Green production process of 2, 3-difluoro-5-chloropyridine with low single impurity content | 江苏丰山集团股份有限公司 | 2022-02-08 | — | — | CN | claimed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4642782-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | Pliant Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025070627-A1 | AZAINDOLE COMPOUND AND MEDICAL DRUG | 日本新薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025068347-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025069270-A1 | AZAINDOLE COMPOUND AND MEDICINE | 日本新薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240245682-A1 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-2528917-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120071494-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071494-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071494-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011094273-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011094273-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-0556737-B1 | Process for the preparation of substituted 2,3-difluoro-pyridines | CLARIANT GMBH (DE) | 2000-01-12 | — | — | EP | disclosed |
| US-5468863-A | Process for the preparation of substituted 2,3-difluoropyridines | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0556737-A1 | Process for the preparation of substituted 2,3-difluoro-pyridines | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |